- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- Pain specialists more comfortable than primary care doctors with prescribing abuse-deterrent opioids, study finds
- Upsher-Smith launches morphine sulfate capsules
- Egalet, Shionogi to develop abuse-deterrent opioids
STAMFORD, Conn. — The Food and Drug Administration has approved a new dosage strength for a chronic pain patch made by Purdue Pharma, the drug maker said Tuesday.
Purdue announced the approval of the 15-microgram-per-hour strength of Butrans (buprenorphine). The drug is used to treat moderate to severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. The new strength is in addition to the 5-microgram, 10-microgram and 20-microgram strengths already on the market, and it will be launched next month.
"The new strength provides another option when adjusting the dose to obtain an appropriate balance between adequate pain relief and opioid-related adverse reactions," Purdue SVP research and development Gary Stiles said.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.